Biotech News

Rallybio Announces Reverse Stock Split of Common Stock

Rallybio (RLYB)Rallybio2026-02-03 21:05 ESTCompany update

NEW HAVEN, Conn. --(BUSINESS WIRE)--Feb. 3, 2026-- Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation (the

Related news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

View all latest news

Rallybio

Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.

Recent company news

RLYBRallybio2026-06-01 12:00 EST

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

RLYBRallybio2026-03-02 13:00 EST

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

RLYBRallybio2026-02-17 13:00 EST

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

RLYBRallybio2026-02-03 21:05 EST

Rallybio Announces Reverse Stock Split of Common Stock

RLYBRallybio2025-11-06 13:00 EST

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

Stock data

Close: 16.19 USD
Market cap: 94.13M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States